Cited by 383

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Eggermont, Alexander M.M, Kirkwood, John M·2004·European Journal of Cancer

DOI 10.1016/j.ejca.2004.04.030

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2004.04.030

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer Statistics, 2002
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Self-citation
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Self-citation
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2745 · Cited by 764
Self-citation
Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends
Howe, H. L., Wingo, P. A., Thun, M. J., Ries, L. A. G., Rosenberg, H. M., Feigal, E. G., & Edwards, B. K. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.11.824 · Cited by 738
Cancer: Principles and Practice of Oncology
Steele, G. D. (1983) · Archives of Surgery · doi:10.1001/archsurg.1983.01390060092027 · Cited by 485
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
Jansen, B., Wacheck, V, Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., & Pehamberger, H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03207-4 · Cited by 482
Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial
Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.044 · Cited by 370
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., & Suciu, S. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00074-4 · Cited by 341
Self-citation
Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson, C. I., Ibrahim, J., Kirkwood, J. M., Coates, A. S., Atkins, M. B., & Blum, R. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1743 · Cited by 303
Self-citation
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials
Huncharek, M. S., Caubet, J.-F., & McGarry, R. C. (2001) · Melanoma Research · doi:10.1097/00008390-200102000-00009 · Cited by 157
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Luikart, S. D., Kennealey, G. T., & Kirkwood, J. M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.164 · Cited by 108
Self-citation
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
Middleton, M. R., Lorigan, P. C., Owen, J., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1056 · Cited by 100
Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma
Young, A. M., Marsden, J. R., Goodman, A. G., et al. (2001) · Clinical Oncology · doi:10.1053/clon.2001.9314 · Cited by 64
Medical management of melanoma
Brown, C. K., & Kirkwood, J. M. (2003) · Surgical Clinics of North America · doi:10.1016/s0039-6109(02)00187-1 · Cited by 30
Self-citation
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study
Jelić, S., Babović, N. L., Kovčin, V., et al. (2002) · Melanoma Research · doi:10.1097/00008390-200202000-00013 · Cited by 17
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial
Ravaud, A., Delaunay, M. M., Chevreau, C., Coulon, V., Debled, M., Bret-Dibat, C., Courbon, F., Gualde, N., & Bui, B. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2120 · Cited by 16

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Self-citation
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
O'Day, S. J., Eggermont, A. M. M., Chiarion-Sileni, V., Kefford, R., Grob, J. J., Mortier, L., Robert, C., Schachter, J., Testori, A., Mackiewicz, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5585 · Cited by 373
Self-citation
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study
Gray, R. H., Li, X., Kigozi, G., Serwadda, D., Brahmbhatt, H., Wabwire-Mangen, F., Nalugoda, F., Kiddugavu, M., Sewankambo, N., Quinn, T. C., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67481-8 · Cited by 358

See all 383

Authors: Eggermont, A. M. M., & Kirkwood, J. M.
Venue: European Journal of Cancer
Publisher: Elsevier BV
Published: 2004-08
Volume: 40
Issue: 12
Pages: 1825-1836
ISSN: 0959-8049 (ISSN-L)
DOI: 10.1016/j.ejca.2004.04.030
OpenAlex: W2011852843
Cited by: 383
References: 20
FWCI: 8.08
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources